• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

  • About
    • General Information
    • Disease Research
    • Training & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti Aging Study
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Osteoarthritis
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Ways to Give
    • Tax Credit
    • Planned Giving
    • Contact Philanthropy
Home - OMRF News - Archives for Merrill-Joan-T

Merrill-Joan-T

Tissue Factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients.

Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies.

What Did Not Work: The Drug or the Trial?

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset.

SARS-CoV-2 vaccines in patients with SLE.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Interim pages omitted …
  • Page 36
  • Go to Next Page »

Before Footer

Equal Opportunity Employer

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Ethics Point
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Ethics Point
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayTop Workplace